Pieris Pharmaceuticals
Pieris Pharmaceuticals
PIRS
NASDAQ
28.44
USD
-1.93%
About
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB.
Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time.
S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 32.1K |
| Three Month Average Volume | 2.9M |
| High Low | |
| Fifty-Two Week High | 28 USD |
| Fifty-Two Week Low | 6.2 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 12 Jul 2024 |
| Price and Volume | |
| Current Price | 18.4 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.15% |
| Thirteen Week Relative Price Change | 69.38% |
| Twenty-Six Week Relative Price Change | 20.91% |
| Fifty-Two Week Relative Price Change | -45.90% |
| Year-to-Date Relative Price Change | 6.72% |
| Price Change | |
| One Day Price Change | -0.38% |
| Thirteen Week Price Change | 81.28% |
| Twenty-Six Week Price Change | 32.95% |
| Five Day Price Change | 1.83% |
| Fifty-Two Week Price Change | -32.21% |
| Year-to-Date Price Change | 26.37% |
| Month-to-Date Price Change | 10.84% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 21.63679 USD |
| Book Value Per Share (Most Recent Quarter) | 14.16788 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 21.63679 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 14.16788 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.04421 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 38.02629 USD |
| Revenue Per Share (Trailing Twelve Months) | 16.66806 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -21.8005 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -19.12498 USD |
| Normalized (Last Fiscal Year) | -2.7607 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -21.8005 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -19.12498 USD |
| Including Extraordinary Items (Last Fiscal Year) | -21.8005 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -19.12498 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 21.31981 USD |
| Cash Per Share (Most Recent Quarter) | 14.94501 USD |
| Cash Flow Per Share (Last Fiscal Year) | -20.10926 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -11.81506 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -30.28553 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -129 |
| Cash Flow Revenue (Trailing Twelve Months) | -182 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -114.11% |
| Pretax Margin (Last Fiscal Year) | -57.33% |
| Pretax Margin (5 Year) | -94.51% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -69.51% |
| Operating Margin (Trailing Twelve Months) | -123.55% |
| Operating Margin (5 Year) | -99.17% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -57.33% |
| Net Profit Margin (Trailing Twelve Months) | -114.11% |
| Net Profit Margin (5 Year) | -94.61% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -18.18% |
| Tangible Book Value (5 Year) | -7.70% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | 8.03% |
| Revenue Change (Trailing Twelve Months) | -37.15% |
| Revenue Per Share Growth | -2.81% |
| Revenue Growth (5 Year) | 13.44% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -36.82% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -176.31% |
| EPS Change (Trailing Twelve Months) | 35.62% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -19,731,000 |
| Net Debt (Last Fiscal Year) | -26,366,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -53,990,000 |
| Free Cash Flow (Trailing Twelve Months) | -37,924,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -36.58% |
| Return on Assets (Trailing Twelve Months) | -42.31% |
| Return on Assets (5 Year) | -28.41% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -89.76% |
| Return on Equity (Trailing Twelve Months) | -80.46% |
| Return on Equity (5 Year) | -86.97% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -57.30% |
| Return on Investment (Trailing Twelve Months) | -66.27% |
| Return on Investment (5 Year) | -39.69% |